Decreased levels of topoisomerase IIα human renal cell carcinoma lines resistant to etoposide

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 10, 1997, Pages 546-554

  Scheltema, Johan M W ^a,b   Romijn, Johan C ^a   Van Steenbrugge, Gert J ^a   Beck, William T ^b   Schröder, Fritz H ^a   Mickisch, Gerald H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Cultured tumor cells; DNA topoisomerase II; Drug resistance; Renal cell carcinoma

Indexed keywords

DOXORUBICIN; ETOPOSIDE;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CROSS RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS REGULATION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DNA METHYLATION; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION; HUMANS; ISOENZYMES; KIDNEY NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0030732995     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050103     Document Type: Article

References (49)

1. Beck WT, Danks MK, Wolverton JS, Chen M, Granzen B, Kim R, Suttle DP (1994a) Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 29:145-169
2. Beck WT, Kim R, Chen M (1994b) Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells. Chemother Pharmacol 34:32-40
3. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchers KL, Freeman MH, Goldenberg GJ (1995) Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55:78-82
4. Cedar H (1988) DNA methylation and gene activity. Cell 53:3-4
5. Chung TDY, Drake FH, Tan KB, Per SR (1989) Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86:9431-9435
6. Cole SP, Bahrdway G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RGN (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
7. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA toposomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869
8. Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT (1993) Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res 53:1373-1379
9. Devore RF, Corbett AH, Osheroff N (1992) Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA clevage religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinyl-amino)methane-sulfon-m-anisidide. Cancer Res 52:2156-2161
10. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST, Mirabelli CK (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of enzyme. J Biol Chem 262:16739-16747
11. Friche E, Danks MK, Schmidt CA, Beck WT (1991) Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res 51:4213-4218
12. Friche E, Danks MK, Beck WT (1992) Characterization of tumor cell resistance to 4′-deoxy-4′-iododoxorubicin developed in Ehrlich ascites cells in vivo. Cancer Res 52:5701-5706
13. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID (1991) Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51:6592-6595
14. Gekeler V, Beck J, Noller A, Wilisch A, Frese G, Neumann M, Handgretinger R, Ehninger G, Probst H, Niethammer D (1994) Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemothera-peutically treated leukemias. Ann Hematol 69:19-24
15. Grossi FS, Zhao X, Romijn JC, Ten-Kate FJ, Schröder FH (1992) Metastatic potential of human renal cell carcinoma: experimental model using subrenal capsule implantation in athymic nude mice. Urol Res 20:303-306
16. Gudkof AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, Roninson IB (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90:3231-3235
17. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH (1995) Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55:1707-1716
18. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase. Cancer Res 51:4729-4731
19. Hochhauser D, Harris AL (1993) The role of topoisomerase II alpha and beta in drug resistance Cancer Treat Rev 19:181-194
20. Hochhauser D, Stanway CA, Harris AL, Hickson ID (1992) Cloning and characterization of the 5′-flanking region of the human topoisomerase II alpha gene. J Biol Chem 267:18961-18965
21. Jones PA, Buckley JD (1990) The role of DNA methylation in cancer. Adv Cancer Res 54:1-23
22. Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I (1988) Measurement of multidrug-resistance messenger RNA in urogenital cancers: elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 139:862-865
23. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J (1993) Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53:4251-4256
24. Kanamuru H, Kaheki Y, Yoshida O, Nakanishi S, Pastan I, Gottesmann MM (1989) MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 81:844-849
25. Kaufmann S, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ (1994) Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83:517-530
26. Kim R, Beck WT (1994) Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression. AP-1 DNA-binding activity, and formation of jun/fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26, Cancer Res 54:4958-4966
27. Kimura K, Saijo M, Ui M, Enomoto T (1994) Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem 269:1173-1176
28. Kubo T, Kohno K, Ohga T, Taniguchi K, Kawanami K, Wada M, Kuwano M (1995) DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res 55:3860-3864
29. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375
30. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258:15365-15370
31. Loflin PT, Hochhauser D, Hickson ID, Morales F, Zwelling LA (1994) Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase II alpha gene promotor. Biochem Biophys Res Commun 200:489-496
32. Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken PM (1990) Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 50:3670-3674
33. Mickisch GH, Noordzij MA, Gaast A van der, Gebreamlack P, Köhrmann KU, Mogler Drautz E, Kupper H, Schröder FH (1996) Dexvarapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 121:11-16
34. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon Cardo C, O'Brien JP (1995) Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin oncol 13:1958-1965
35. Nitiss JL, Liu YX, Hsiung Y (1993) A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53:89-93
36. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Hoff DD von, Roninson IB (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160-6164
37. Osheroff N, Corbett AH, Robinson M (1994) Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol 29:105-126
38. Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32:103-108
39. Ritke MK, Yalowich JC (1993) Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 46:2007-2020
40. Romijn JC, Verkoelen CF, Schröer FH (1988) Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12:99-110
41. Takano H, Kohno K,Ono M,Uchida Y, Kuwano M (1991) In- creased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51:3951-3957
42. Tan K, Dorman TE, Falls KM, Chung TD, Mirabelli CK, Crooke ST, Mao J (1992) Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 52:231-234
43. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85:7177-7181
44. Volm M, Kastel M, Mattern J, Efferth T (1993) Expression of resistance factors (P-glycoprotein, glutathione 5-transferase-pi, and topoisomerase II) and their interrelationship to protooncogene products in renal cell carcinomas. Cancer 71:3981-3987
45. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield, Sikorska M (1991) Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 51:1078-1085
46. Wang JC (1987) Recent studies of DNA topoisomerases. Biochim Biophys Acta 909:1-9
47. Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK (1990) Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res 50:2901-2908
48. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK (1992) Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 4:481-488
49. Yagoda A, Abi Rachel B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60